BCRX:NGS-BioCryst Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 6.17

Change

0.00 (0.00)%

Market Cap

USD 0.44B

Volume

2.94M

Analyst Target

USD 8.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biocryst Pharmaceuticals Inc is a biotechnology company. The Company designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.13 (-0.24%)

USD 122.24B
REGN Regeneron Pharmaceuticals Inc

+7.30 (+0.69%)

USD 115.08B
MRNA Moderna Inc

+0.60 (+0.44%)

USD 51.07B
ALNY Alnylam Pharmaceuticals Inc

+17.25 (+7.74%)

USD 28.20B
ARGX argenx NV ADR

+10.96 (+2.49%)

USD 26.78B
BNTX BioNTech SE

-2.23 (-2.57%)

USD 20.40B
BGNE BeiGene Ltd

-8.16 (-5.13%)

USD 17.50B
GMAB Genmab AS

-0.04 (-0.15%)

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

-0.17 (-0.20%)

USD 15.98B
RPRX Royalty Pharma Plc

-0.21 (-0.77%)

USD 15.90B

ETFs Containing BCRX

ETLI:F Legal & General UCITS ETF.. 2.77 % 0.00 %

+0.24 (+1.75%)

USD 0.02B
ETLI:XETRA L&G Pharma Breakthrough U.. 2.77 % 0.00 %

+0.01 (+1.75%)

USD 0.02B
BIOT:SW L&G Pharma Breakthrough U.. 2.77 % 0.00 %

+0.15 (+1.75%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 2.59 % 0.00 %

+0.50 (+1.75%)

USD 0.02B
CURE:AU 1.23 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.01% 63% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.01% 63% D 62% D
Trailing 12 Months  
Capital Gain -16.73% 58% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.73% 58% F 38% F
Trailing 5 Years  
Capital Gain 70.91% 80% B- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.91% 80% B- 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 58.57% 87% B+ 92% A
Dividend Return 58.57% 87% B+ 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 129.76% 20% F 12% F
Risk Adjusted Return 45.13% 91% A- 76% C+
Market Capitalization 0.44B 84% B 75% C

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 56.59 3% 2%
Price / Cash Flow Ratio -13.38 85% 85%
Price/Free Cash Flow Ratio -12.20 90% 86%
Management Effectiveness  
Return on Equity -1,925.37% 3% 1%
Return on Invested Capital 56.90% 91% 96%
Return on Assets -10.85% 87% 33%
Debt to Equity Ratio -178.09% 90% 95%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.